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Abstract
Introduction: This study investigated the promising effect of a new Platelet Glue obtained from Cryoprecipitation
of Apheresis Platelet products (PGCAP) used in combination with Mesenchymal Stromal Cells (MSC) loaded on
ceramic biomaterials to provide novel strategies enhancing bone repair.
Methods: PGCAP growth factor content was analyzed by ELISA and compared to other platelet and plasma-
derived products. MSC loaded on biomaterials (65% hydroxyapatite/35% beta-TCP or 100% beta-TCP) were
embedded in PGCAP and grown in presence or not of osteogenic induction medium for 21 days. Biomaterials
were then implanted subcutaneously in immunodeficient mice for 28 days. Effect of PGCAP on MSC was evaluated
in vitro by proliferation and osteoblastic gene expression analysis and in vivo by histology and
immunohistochemistry.
Results: We showed that PGCAP, compared to other platelet-derived products, allowed concentrating large
amount of growth factors and cytokines which promoted MSC and osteoprogenitor proliferation. Next, we found
that PGCAP improves the proliferation of MSC and osteogenic-induced MSC. Furthermore, we demonstrated that
PGCAP up-regulates the mRNA expression of osteogenic markers (Collagen type I, Osteonectin, Osteopontin and
Runx2). In vivo, type I collagen expressed in ectopic bone-like tissue was highly enhanced in biomaterials
embedded in PGCAP in the absence of osteogenic pre-induction. Better results were obtained with 65%
hydroxyapatite/35% beta-TCP biomaterials as compared to 100% beta-TCP.
Conclusions: We have demonstrated that PGCAP is able to enhance in vitro MSC proliferation, osteoblastic
differentiation and in vivo bone formation in the absence of osteogenic pre-induction. This clinically adaptable
platelet glue could be of interest for improving bone repair.
Introduction
Despite years of ongoing research, reconstruction of
large bone defects, resulting from a variety of pathologi-
cal events (trauma and surgical treatment of tumors),
remains a challenging clinical problem. Classic therapeu-
tic approaches rely on autologous cancellous bone graft,
which today is considered the ‘gold standard’ treatment
[1]. However, the use of autograft, which often results in
a favorable clinical outcome, is limited in quantity and
is associated with complications at the harvesting site
[2]. Bone tissue engineering has emerged as a promising
approach based on the elaboration of a bone substitute
mimicking bone autograft, which contains all of the key
components required for bone repair: (a) an osteocon-
ductive scaffold, (b) cells with osteogenic potential, and
(c) growth factors for osteoinduction and vascularization
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The main outcomes for a biomaterial are to fill the
defect, to replace bone in the short term, and to favor
bone formation and remodeling in the long term. The
fine tuning of both porosity and chemical composition
should be optimal to allow cell migration, proliferation,
differentiation, vascular invasion without inducing
immune rejection and degradation with time in non-
toxic products. Among a large assortment of three-
dimensional scaffolds, calcium phosphate ceramics,
which possess excellent biocompatibility due to their
close resemblance to bone mineral, should be a good
candidate for bone tissue engineering [4,5].
Adult mesenchymal stromal cells (MSCs) [6], fibro-
blast-like cells that can be isolated from bone marrow
or other connective tissues [7], can be easily expanded
in vitro. These cells are further characterized by their
multi-potential capacity for differentiation into osteo-
blasts, chondrocytes, and adipocytes [8]. Thus, the hom-
ing ability of MSCs to injury sites, their paracrine
secretions enhancing cell migration, differentiation, or
angiogenesis as well as their immunomodulatory proper-
ties make them an ideal cell type for bone repair [9]. In
vivo, MSCs coming from a perivascular site or perios-
teum are involved in direct or secondary fracture heal-
ing by their osteogenic and chondrogenic differentiation
potential [10]. Locally injected or pre-seeded MSCs on
different kinds of biomaterials can enhance the repair of
critical size defect in animal models [11,12]. Several
teams have obtained significant clinical results after
MSC allogenic graft in osteogenesis imperfecta [13,14]
or after implantation of hydroxyapatite biomaterials
loaded with autologous MSCs [15,16].
The third important fate for bone healing is osteoin-
duction. Platelets play an essential role in wound healing
and are the main regulators of the inflammatory phase.
In fact, upon activation, platelets release growth factors
and inflammatory molecules from their granule a.
These molecules have been shown to enhance MSC
proliferation and differentiation in vitro [17], angiogen-
esis, fibroblast proliferation, and extracellular matrix
deposition [18,19]. Thus, administration of platelet con-
centrates named platelet-rich plasma (PRP) has been
evaluated in several pre-clinical and clinical studies
demonstrating their capacity to improve, for example,
dental implant surgery, orthopedic surgery, muscle and
tendon repair, and skin ulcers [20-22]. Controversial
results in the field of bone repair have been obtained
with the use of platelet-derived products [23-26] and
could be explained by the diversity of preparations and
terms of use. Despite these discrepancies, MSCs com-
bined to platelet-derived products with or without bio-
materials seem to improve bone healing [27,28].
Various studies were performed to improve osteoin-
duction processes such as in vitro chemical pre-
conditioning [29], in vitro platelet lysate (PL) priming
[30,31], or in vitro osteogenic pre-induction [32] of
implanted MSCs. However, the exact mechanisms of
action of these in vitro preparations on in vivo bone for-
mation are not well understood. Furthermore, the inter-
actions between the various components used
(biomaterial, cells, and osteoinductive factors) have to be
investigated. For this purpose, we used an ectopic model
of bone formation in which it is possible to investigate
various actors involved in bone formation [33].
In the present study, we first developed a simple inno-
vative process that is clinically adaptable, producing a
platelet glue obtained from cryoprecipitation of apher-
esis platelet products (PGCAP), highly concentrated in
fibrinogen and growth factors. Next, we studied whether
MSCs pre-cultured with or without osteoblast-inductors
loaded on various types of biomaterials (composition
and porosity) and combined or not to PGCAP could
enhance in vivo ectopic bone formation.
Materials and methods
Platelet glue obtained from cryoprecipitation of apheresis
platelet products and platelet lysate preparation
PGCAP and PL were made from platelet apheresis col-
lections performed at the Centre de Transfusion San-
guine des Armées (Clamart, France). All apheresis
products were biologically qualified in accordance with
French legislation. Only samples containing about 1 ×
109 platelets per milliliter were selected. For PL prepara-
tion, apheresis products were frozen at -40°C for lysing
platelets and releasing growth factors. PL products were
thawed and used in culture as fetal calf serum (FCS)
substitute or for enzyme-linked immunosorbent assays
(ELISAs). For PGCAP preparation (Figure 1), apheresis
platelet concentrate was activated by glass contact and
PGCAP was obtained through a protein cryoprecipita-
tion process. A centrifugation was able to separate the
supernatant named platelet-poor plasma (PPP) and the
cryoprecipitate named PGCAP, which is composed of
fibrinogen, pre-activated factors of coagulation, and pla-
telet growth factors. For in vitro and in vivo experi-
ments, three different mixes of PGCAP prepared from
five different donors were used.
Enzyme-linked immunosorbent assay
ELISA (Quantikine; R&D Systems, Minneapolis, MN,
USA) was used to quantify the concentration of EGF
(DEG00), basic FGF (HSFB75), HGF (DHG00), IGF-1
(DG100), PDGF-AB (DHB00B), TGF-b1 (DB100), VEGF
(#DVE00), SDF-1a (DSA00), IL-1a (DLA50), and IL-1b
(DLB50) in PGCAP, PPP, PL, Tissucol (TC) (Baxter,
Deerfield, IL, USA), and FCS. All sample measurements
were performed in duplicate. The lower detection limits
of these assays were 0.7 pg/mL for EGF, 0.22 pg/mL for
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basic FGF, 40 pg/mL for HGF, 0.024 ng/mL for IGF-1,
1.7 pg/mL for PDGF-AB, 7 pg/mL for TGF-b1, 9 pg/mL
for VEGF, 18 pg/mL for SDF-1a, 1 pg/mL for IL-1a,
and 1 pg/mL for IL-1b. The total protein content of
PGCAP, PPP, PL, TC, and FCS was determined by
using Quick start Bradford dye reagent (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). Results were expressed
as picograms of factors per 1 mg of protein ± standard
error of the mean (SEM).
MSC isolation and culture
Human bone marrow MSCs were obtained with
informed consent from different patients undergoing
routine total hip replacement surgery in the Percy
Hospital (Clamart, France). Ethical approval for research
studies on human material was given by Service de
Santé des Armées (Minister of Defense). As previously
reported [17], bone marrow mononuclear cells
(BMMNCs) were isolated from the supernatant of spon-
gious bone fragments, plated at a density of 100 × 103
cells/cm2, and cultured at 37°C in 95% air and 5% CO2
in alpha-minimum essential medium (a-MEM) (Biologi-
cal Industries, Kibbutz Beit-Haemek, Israel) with 10 μg/
mL ciprofloxacin (Ciflox 400 mg/200 mL; Bayer Pharma,
Leverkusen, Germany) and 10% pre-screened FCS (FCS
medium) or 5% PL (PL medium) complemented with 2
UI/mL heparin to avoid platelet gel formation [17].
After 3 to 4 days, non-adherent cells were removed and
Figure 1 Preparation of platelet glue obtained from cryoprecipitation of apheresis platelets.
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cultures were re-fed with fresh medium. Thereafter, cul-
tures were fed at 3- to 4-day intervals. When the cells
reached confluence, they were detached by using 1X
trypsin-EDTA (Gibco, now part of Invitrogen Corpora-
tion, Carlsbad, CA, USA) and replated at 4,000 cells/
cm2. For in vivo experiments, MSCs were transduced by
lentiviral vector pRRL WPRE PGK/GFP cPPT and were
purified to obtain more than 95% GFP+ cells. Expanded
MSCs were validated according to their classic phenoty-
pic markers by flow cytometry, their clonogenic poten-
tial (CFU-F assay), and their multi-lineage differentiation
potential (osteogenic, adipogenic, and chondrogenic)
[17].
Porous ceramic biomaterials
Calciresorb (Ceraver, Roissy, France) is a novel bone graft
substitute that is used for the repair of bony voids or gaps
of the skeletal system in humans. Two groups of Calcire-
sorb biomaterials were used: (a) ‘Calciresorb’ biomaterials
(2 to 3 mm in diameter) and (b) ‘Calciresorb bone like’
biomaterials (cubes of 4 × 4 × 4 mm3) (Table 1). In each
group, three chemical compositions were evaluated: (a)
beta-tricalcium phosphate (b-TCP) 35%-hydroxyapatite
(HA) 65%, (b) b-TCP 75%-HA 25%, and (c) b-TCP 100%
(Table 2). Before culture, biomaterials were sterilized by
gamma irradiation at a minimum dose of 25 KGy. Scan-
ning electron microscopy was used to characterize the
morphology and the structure of the scaffolds.
Preparation of MSC/biomaterial constructs
PGCAP effect was first evaluated by seeding MSCs in
PGCAP or TC (27,000 cells/in products). Obtained
cells/products were grown on 6-well plates. In other
experiments, MSCs were loaded on biomaterials at a dif-
ferent cell seeding density: 1 × 105 (biocompatibility
analysis) or 2 × 105 cells (for experiments that combined
in vitro (proliferation and osteogenic differentiation stu-
dies) and in vivo studies). Cellular suspension (200 μL)
was added on biomaterial, incubated for 3 hours, and
gently agitated every 30 minutes to allow cell attach-
ment. Before cell seeding, biomaterials were maintained
in a-MEM overnight at 4°C.
For preparation of TC alone or biomaterials embedded
in TC, freeze-dried human fibrinogen and thrombin were
re-suspended, respectively, at 18 mg/mL and 2.5 UI/mL in
2% NaCl and 1.5 mM CaCl2 solution. MSCs were mixed
with 100 μL of fibrinogen and with 100 μL of thrombin,
immediately added on 6-well plates or biomaterials, and
incubated for 15 minutes at 37°C to allow coagulation. For
preparation of PGCAP alone or biomaterials embedded in
PGCAP, MSCs were mixed in 200 μL of solution contain-
ing 50% PGCAP, 4.68 g/L NaCl, 0.8 g/L CaCl2, and 10 μg/
mL exacyl [34], immediately added on wells or biomater-
ials, and incubated for 60 minutes at 37°C to allow coagu-
lation. The various biomaterial constructs were then
placed into 6- or 24-well culture plates in culture medium.
Cell-free scaffolds were incubated under similar conditions
and were used as controls.
Quantification of cell proliferation
Cells seeded on 6-well plates or on biomaterials were
rinsed with TE buffer 1x (10 mM Tris-HCl, 1 mM EDTA,
pH 7.5), lysed with TE 1x 0.1% triton (Sigma-Aldrich, St.
Louis, MO, USA) and 0.2 mg/mL proteinase K (Roche
Applied Science, Indianapolis, IN, USA), and incubated
overnight at 52°C. Then samples were frozen/thawed
three times at -80°C, sonicated 15 minutes, and vortexed 1
minute. Afterward, 100 μL of lysate (with optimal dilution)
was incubated in 96-well plates 10 minutes in a darkroom
at room temperature with 100 μL of diluted Quant-iTTM
PicoGreen double-stranded DNA (dsDNA) reagent (Mole-
cular Probes, now part of Invitrogen Corporation), which
is an ultrasensitive fluorescent nucleic acid stain for quan-
tifying dsDNA in solution. Sample fluorescence was mea-
sured by using a fluorescence microplate reader at
excitation and emission wavelengths of 485 and 535 nm,
respectively, as recommended by the manufacturer.
Results were compared with standard curves of series of
cell dilutions (lysed as described above) and allowed us to
establish a correlation between dsDNA quantity and num-
ber of cells. To exclude measurement errors, all experi-
ments were carried out in triplicate.
Table 1 Physical characteristics of biomaterials given by
Ceraver
Biomaterials Calciresorb Calciresorb bone like
Porosity 65% ± 5% 75% ± 5%
Pore size 100 to 400 μm 500 μm
Macroporosity 60% 100%
Microporosity 40% -
Interconnectivity Unknown 96% to 100%
Interconnected pore diameter Variable 50 μm < F < 250 μm
Table 2 Chemical characteristics of biomaterials given by
Ceraver
Sample list Composition Biomaterials
HA b-TCP
BMA 65% 35%
BMB 25% 75% Calciresorb
BMC - 100%
BMD 65% 35%
BME 25% 75% Calciresorb bone like
BMF - 100%
b-TCP, beta-tricalcium phosphate; BM, biomaterial; HA, hydroxyapatite.
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Osteogenic differentiation assays
To induce osteogenic differentiation of MSCs, the differ-
ent constructs were placed in FCS medium alone (not
induced-MSC = ni-MSC) or supplemented (osteogenic
induced-MSC = i-MSC) with 0.1 μM dexamethasone, 0.05
mM L-ascorbic acid-2-phosphate, and 10 mM b-glycero-
phosphate (all from Sigma-Aldrich) for 21 days of culture.
Medium was changed twice a week. For quantitative real-
time reverse transcription-polymerase chain reaction (RT-
PCR), on day 21, cells were lysed in RLT buffer for RNA
extraction (Qiagen, Hilden, Germany). Total RNA was
extracted from various MSC biomaterial constructs by
using RNeasy a micro- or mini-kit as described by the
manufacturer (Qiagen) and treated with DNAse (Roche,
Basel, Switzerland). cDNA was synthesized from 0.5 μg of
total RNA by using Random Hexamer Primer and Multi-
scribe RT (Applied Biosystems, Foster City, CA, USA).
Gene expression was quantified by real-time PCR by using
the LightCycler Fast Start DNA Master (Roche) with 0.2
μL of cDNA corresponding to 2 ng of total RNA in a 20-
μL final volume, 2.25 mM MgCl2, and 0.5 μM of each pri-
mer. PCR was performed for 45 cycles at 95°C for 15
seconds, at the specific annealing temperature for 25 sec-
onds, and at 72°C for 30 seconds. Amplification specificity
was checked by using a melting curve. Specific gene pri-
mers for each factor of interest were designed for real-time
PCR analysis by using Primer3 and Ensembl software
(Table 3). Results were analyzed with LightCycler software
version 3.5 (Roche) by using the second derivative maxi-
mum method to set the threshold cycle (CT). Quantitative
analysis was carried out by using standard curves and nor-
malization with the GeNorrm software and methodology
[35], with four reference genes: glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), b-actin, b-2-microglobulin, and
hypoxanthine phosphoribosyltransferase 1 (HPRT).
Animal model
Thirty Swiss nude mice (6 weeks old; Charles River
Laboratories, Inc., Wilmington, MA, USA) were used in
these experiments, kept in a controlled environment, and
treated in accordance with the institutional animal guide-
lines. MSCs loaded on BMA or BMF embedded or not in
PGCAP were cultured in the presence or absence of osteo-
genic induction medium for 21 days. On each mouse, four
implants per condition were grafted. Avertine was used for
anesthesia to proceed to incisions on a 5-mm length to
create subcutaneous pockets. Biomaterials were implanted
in the upper part of the back, and next the skin was closed
by suture with non-absorbable thread. After 28 days, the
animals were euthanized by inhalation of carbon dioxide.
The samples were harvested, washed once in PBS, and
immediately put in paraformaldehyde (PFA) 4% (confocal
microscopy analysis) or in formol fixative (histology analy-
sis). This protocol was approved by the ethics committee
for animal experiments of the Army Biomedical Research
Institute of Bretigny-sur-Orge.
Confocal microscopy
Adhesion, proliferation, and persistence of MSCs on
various biomaterials were assessed by using confocal
microscopy. The cell-seeded scaffolds were cut in four
slices and fixed with PFA 4% for 60 minutes at room
temperature. Fixed samples were rinsed with PBS and
incubated with blocking buffer (PBS, 2% human albu-
min, and 5 mg/mL human immunoglobulin; LFB, Les
Ulis, France) for 1 hour at 4°C, followed by overnight
incubation with the primary antibody (IgG1-APC or
CD90-APC; Beckman Coulter, Inc., Fullerton, CA, USA)
at 4°C in blocking buffer. After washing with PBS,
samples were counterstained with 4’-6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich) at 300 ng/mL for
1 hour. Images were obtained and processed by using
a TCS SPE confocal microscope (Leica, Wetzlar,
Germany) with a ×20 objective (numerical aperture of
0.75). The excitation lasers used were 405 nm to image
nuclei stained with DAPI and 488, 532, and 635 nm
to image MSC GFP+, Biomaterial (reflectance), and
CD90APC, respectively.
Table 3 Polymerase chain reaction primers used to investigate osteoblastic cell differentiation
Gene Identification Forward primer Reverse primer
Alkaline phosphatase NM_000478 GGCCCTACAATGCTCATGTC TGGTGGTCTTGGAGTGAGTG
Collagen type I, alpha 1 NM_000088 GAATGGAGATGATGGGGAAG CCATCCAAACCACTGAAACC
Osteocalcin (Bglap) NM_199173 GACTGTGACGAGTTGGCTGA GCAAGGGGAAGAGGAAAGAA
Osteonectin (Sparc) NM_003118 GGGCTTCTCCTCCTCTGTCT AACCGATTCACCAACTCCAC
Osteopontin (Spp1) NM_001040058 GCCGAGGTGATAGTGTGGTT CATTCAACTCCTCGCTTTCC
Runx 2 NM_001024630 GCACTGGGTCATGTGTTTGA GGCTGCATTGAAAAGACTGC
b-Actin NM_001101 TCGTGCGTGACATTAAGGAG AGGAAGGAAGGCTGGAAGAG
b-2-microglobulin NM_004048 TGTCTTTCAGCAAGGACTGG CCTCCATGATGCTGCTTACA
Gapdh NM_002046 CCAGGTGGTCTCCTCTGACT GGTGGTCCAGGGGTCTTACT
Hprt1 NM_000194 GACCAGTCAACAGGGGACAT CTTGCGACCTTGACCATCTT
Gapdh, glyceraldehyde-3-phosphate dehydrogenase; hprt1, hypoxanthine phosphoribosyltransferase 1.
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Histology and immunohistochemistry
Implanted biomaterials were rinsed and immersed in
formol for 1 day. The various biomaterials were decalci-
fied with 0.1 M EDTA 2Na for 3 to 4 days (Calciresorb
biomaterials) or with 0.6 M EDTA 2Na for 14 to 21
days (Calciresorb bone like biomaterials). Biomaterials
were rinsed with PBS, re-fixed with formol, and then
dehydrated with a graded series of ethanol treatment
prior to being embedded in paraffin. Paraffin sections of
5-μm thickness were dried, deparaffinized, and stained
with hematoxylin, phloxin, and safranin or treated for
immunohistochemistry.
For collagen immunohistological staining [36], sections
were pre-treated with 2 mg/mL hyaluronidase (Merck,
Whitehouse Station, NJ, USA) for 15 minutes at 37°C
and subsequently with 1 mg/mL pronase (Sigma-Aldrich)
for 30 minutes at 37°C. Endogenous peroxidases were
blocked by using 3% H2O2 for 5 minutes. Non-specific
background was blocked by using TBS1X containing 10%
FBS for 45 minutes. Sections were incubated overnight at
4°C with monoclonal mouse anti-human type I collagen
(clone I-8H5, 1 μg/mL; Acris Antibodies, San Diego, CA,
USA). The Envision™ FLEX+ (Dako, Glostrup, Denmark)
with Dako autostainer instrument was then used for
staining analysis.
Bone formation area was quantified by using stained his-
tological sections. Images were analyzed with Photoshop
and ImageJ software. The ratio of all bone formation area
on total biomaterial area was measured on three to five
sections at different levels of the biomaterial (near the sur-
face and in the center of biomaterial).
Statistical analysis
For cell growth analysis, all measurements were per-
formed on three different sources of MSCs and three dif-
ferent batches of PGCAP. In vivo experiments were
performed in triplicate. All data are expressed as mean ±
SEM. Statistical comparisons were made by using analy-
sis of variance (ANOVA) in which a P value of less than
0.05 was considered significant. Differences between
groups or individual conditions were evaluated by using
Student Newman-Keuls test.
Results
PGCAP is enriched in growth factors and SDF-1a and
promotes MSC and osteoprogentitor proliferation
We aimed to determine whether PGCAP was enriched in
growth factors involved in MSC proliferation and bone
repair. For this purpose, we first quantified growth factor,
cytokine, and chemokine contents of PGCAP, PPP, PL,
TC, and FCS by ELISA. Our results showed that EGF,
FGF-b, HGF, PDGF-AB, TGF-b1, and VEGF concentra-
tions were significantly higher in PGCAP than in PPP (3.65
-, 3.04-, 1.74-, 3.38-, 138.4-, and 6.03- fold, respectively)
and in PL (6.52-, 2.41-, 1.13-, 10.28-, 1.84-, and 5.83-fold,
respectively) (Table 4). Few factors were detected in TC
and FCS as compared with PGCAP (Table 4), according to
their plasmatic origin. We also found that chemokine SDF-
1a concentration was significantly higher in PGCAP than
in PPP (5.69-fold), PL (3.9-fold), TC (2.19-fold), and FCS
(3.8-fold). In contrast, IGF-1 concentration was slightly
higher in PPP and PL than in PGCAP. Few concentrations
of IL-1a and IL-1b were detected in PGCAP, although IL-
1b was slightly higher in PGCAP than in PPP (Table 4).
We further showed that fibrinogen was highly concen-
trated in PGCAP as compared with PPP and was similar to
TC (data not shown). Together, these results suggest that
the cryoprecipitation process allows concentrating plasma
and platelet-related molecules such as fibrinogen, growth
factors, and SDF-1a.
The influence of PGCAP on MSC phenotype was
investigated at each culture passage (from P0 to P3) by
flow cytometry. We showed that MSC phenotypic profile
was unchanged regardless of the culture condition since
more than 98% of expanded MSCs were positive for
CD90, CD105, and CD73 and were negative for CD45
(data not shown).
As indicated by results from Table 4, a higher amount of
growth factors was present in PGCAP than in TC pro-
ducts. Therefore, we further studied the impact of PGCAP
or TC on MSC proliferation at different times of osteo-
blastic differentiation (Figure 2). ni-MSC and i-MSC
proliferation was highly enhanced in PGCAP as compared
with TC condition at day 14 (3.84-fold, P <0.001) and at
day 21 (1.85-fold, P <0.01). These results suggest that
PGCAP enhances proliferation of both MSCs and osteo-
progenitor-induced MSCs.
Physical characteristics and biocompatibility of
biomaterials
Two different biomaterials (Table 1) and three different
compositions (Table 2) of biomaterials were analyzed by
scanning electron microscopy. Pictures shown in Figure
3a illustrate data obtained from Ceraver. To evaluate the
biocompatibility of the various biomaterials selected,
MSCs were seeded on each biomaterial and cultured for
further analysis by scanning electron microscopy and for
proliferation evaluation. As shown in Figure 3a, the
pores of each type of biomaterial were colonized by
MSCs. This suggests that the chemical composition or
structure of biomaterials did not interfere with the cell
colonization.
A kinetic study of MSC proliferation was performed by
using the different biomaterials (Figure 3b). At days 7
and 14 of culture, BMF allowed significantly higher MSC
proliferation than the other biomaterials tested (Figure
3b). Even if BME was less powerful than BMF, we showed
that BME allowed a better MSC proliferation than BMA,
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Table 4 Enzyme-linked immunosorbent assay quantitation of growth factor, cytokine, and chemokine levels in PGCAP,
PPP, PL, TC, and FCS
EGF FGF-b HGF IGF-1 PDGF-AB TGF-b VEGF SDF-1a IL-1a IL-1b
Picograms per 1 mg



























































TC N.D. 0.04 0.07 16.62 0.03 42.91 0.13 65.22 0.23 0.30
FCS N.D. 0.11 N.D. 1,916.29 ±
27.95



























TC n.d. 0.50 0.84 191.08 0.31 493.50 1.50 150.00 0.53 0.68
Ratio PGCAP/
PPP











N.D. 123.31c 292.51 N.
S.














0.15 N.S. 0.41 N.S. 0.88 N.S. 4.3d 0.1 N.S. 0.54 N.S. 0.17 N.S. 0.26 N.S. 1.41 N.
S.
0.09 N.S.
Analysis-of-variance test followed by Student Newman-Keuls test. aP <0.001, bP <0.01, cP <0.05, dP <0.0001. EGF, epidermal growth factor; FCS, fetal calf serum;
FGF-b, fibroblast growth factor-beta; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor-1; IL, interleukin; N.D., not determined; N.S., not significant;
PDGF-AB, platelet-derived growth factor-AB; PGCAP, platelet glue obtained from cryoprecipitation of apheresis platelet products; PL, platelet lysate; PPP, platelet-
poor plasma; SDF-1a, stromal cell-derived factor 1 alpha; SEM, standard error of the mean; TC, Tissucol; TGF-b, transforming growth factor-beta; VEGF, vascular
endothelial growth factor.
Figure 2 PGCAP promotes mesenchymal stromal cell (MSC) and osteoprogenitor proliferation. Not induced-MSCs (ni-MSCs) or osteogenic
induced-MSCs (i-MSCs) were embedded in TC or PGCAP and grown for 21 days. The number of cells was evaluated in each condition at days 7,
10, and 21. Data are expressed as mean ± standard error of the mean. Analysis-of-variance test followed by Student Newman-Keuls test revealed
statistically significant difference between groups (PGCAP and TC) at different times. **P <0.01, ***P <0.001. d, day; PGCAP, platelet glue obtained
from cryoprecipitation of apheresis platelet products; TC, Tissucol.
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Figure 3 Physical characteristics and biocompatibility of biomaterials and mesenchymal stromal cell (MSC) proliferation on the
different biomaterials. (a) Representative scanning electron microscopy images of ‘Calciresorb’ (BMA) and ‘Calciresorb bone like’ (BMF)
biomaterial surfaces are shown. MSCs were loaded on these two biomaterials and grown in platelet lysate (PL) medium. MSC colonization on
the various biomaterials was evaluated by scanning electron microscopy at 14 days of culture. Arrows indicate cells on biomaterials. (b) MSCs
loaded on the various biomaterials at low cell seeding density (100 × 103 cells per biomaterial) were grown in PL medium for 14 days. The
number of cells on the different biomaterials was evaluated at days 4, 7, and 14. The data are expressed as mean ± standard error of the mean.
A statistically significant difference between individual conditions was revealed by analysis-of-variance test followed by Student Newman-Keuls
test. **P <0.01, ****P <0.0001. d, day.
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BMB, BMC, and BMD at days 7 and 14. Between days 0
and 4, the number of cells did not vary between each
condition (data not shown). These results indicate that
the structure of Calciresorb bone like biomaterial com-
bined with a 100% b-TCP chemical composition
improves MSC proliferation. Considering these results,
we decided to use the BMF for further experiments in
comparison with the BMA, which is widely studied and
reported in the literature.
PGCAP improves proliferation of cells loaded on BMA
We further investigated the influence of PGCAP in the
presence or absence of osteogenic inductors on prolifera-
tion of MSCs loaded on biomaterials. A kinetic prolifera-
tion study of ni-MSCs and i-MSCs loaded on BMA and
BMF embedded or not in PGCAP was performed at days
10 and 21. Without PGCAP, we showed that the prolifera-
tion of i-MSCs loaded on BMF was significantly higher at
day 21 than that of ni-MSCs (P <0.05) (Figure 4, left
panel). Furthermore, we showed that the proliferation of
i-MSCs loaded on BMF was significantly higher at day 21
than at day 10 (P <0.05). Therefore, i-MSC proliferation
was significantly higher when loaded on BMF than on
BMA at day 21 (P <0.05) (Figure 4, left panel). Interest-
ingly, ni-MSC proliferation was not improved when loaded
on BMF as compared with BMA, which is contradictory to
our previous results shown in Figure 3b. In fact, owing to
a higher cell seeding density (200 × 103 versus 100 × 103
cells per biomaterial), cell proliferation reaches a plateau
and a difference between the two biomaterials could not
be seen.
In the presence of PGCAP, we showed that osteogenic
induction enhanced the proliferation of MSCs loaded on
BMA embedded in PGCAP regardless of the day of analy-
sis ($P <0.05, Figure 4, right panel). At day 21, the prolif-
eration of i-MSCs embedded in PGCAP was significantly
higher as compared with ni-MSCs regardless of the bio-
material tested (#P <0.05, Figure 4, right panel). Further-
more, we showed that PGCAP enhanced proliferation of
ni-MSCs and i-MSCs loaded on BMA (P <0.05, Figure 4).
These results suggest that PGCAP is able to improve cell
proliferation on BMA (which has a poor proliferative
potential) but that its proliferative effect is less effective on
BMF (which has a high proliferative potential).
PGCAP improves osteogenic differentiation of MSCs
loaded on biomaterials
The influence of PGCAP in the presence or absence of
osteogenic inductors, on osteogenic differentiation
potential of MSCs loaded on BMA and BMF, was next
investigated by osteoblastic gene expression analysis at
day 21 of osteogenic induction (Figure 5). The role of in
vitro osteogenic induction of MSCs on the mRNA
expression of osteogenic markers was further analyzed.
Our results showed that alkaline phosphatase mRNA
expression was upregulated by osteogenic induction in
the absence of PGCAP regardless of the biomaterial
tested (12.2-fold, §P <0.01; Figure 5). These results
obtained here correlated with results from alkaline phos-
phatase activity study, showing that, in the presence of
osteogenic inductors, cells exhibit alkaline phosphatase
activity on both biomaterials (data not shown). In MSCs
loaded on both types of biomaterials, osteogenic induc-
tion downregulated the expression of osteonectin (5.13-
fold, #P <0.001) and Runx2 (1.83-fold, #P <0.05) in the
presence of PGCAP. Osteogenic induction also downre-
gulated the expression of osteocalcin mRNA (7.88-fold,
£P <0.05) in the presence or absence of PGCAP (Figure
5). Type I collagen mRNA expression was downregu-
lated by osteogenic induction medium (10.55-fold,
P <0.01) only in MSCs loaded on BMA embedded in
PGCAP (Figure 5).
Then our results showed that PGCAP enhanced the
osteopontin mRNA expression in ni-MSCs and i-MSCs
loaded on BMA (
$3.26-fold, P <0.05; Figure 5). PGCAP
upregulated the collagen type I mRNA expression in
MSCs loaded on BMA only with ni-MSCs (1.85-fold,
P <0.05; Figure 5). We also showed that PGCAP upregu-
lated Runx2 and osteonectin mRNA expression only in
ni-MSCs regardless of the biomaterials (2.82- and 1.52-
fold, respectively, P <0.05; Figure 5). Surprisingly, alkaline
phosphatase mRNA expression was decreased by PGCAP
in MSCs loaded on both biomaterials in the presence or
absence of osteogenic inductors (4.33-fold, P <0.01), sug-
gesting that PGCAP could contain high levels of osteo-
genic inductors that downregulate alkaline phosphatase
mRNA expression. Therefore, we demonstrate that
PGCAP stimulates by itself the osteogenic differentiation
of MSCs as ascertained by its capacity to upregulate the
mRNA expression of osteogenic markers (collagen type I,
osteonectin, osteopontin, and Runx2).
Ectopic implantation of MSC-loaded biomaterials
embedded in PGCAP promotes bone formation in nude
mice
Bone formation ability of MSC-loaded biomaterials
embedded in PGCAP was investigated after ectopic
implantation in a nude mouse model. BMA and BMF
were tested in combination with ni-MSCs versus i-MSCs,
in the presence or absence of PGCAP. Four weeks after
implantation, biomaterials were analyzed ex vivo by con-
focal microscopy (Figure 6). When unloaded biomaterials
were implanted, we observed mouse cell invasion inside
both BMA and BMF, suggesting that biomaterial implan-
tation induced host cell recruitment. We then tested bio-
materials in the presence of GFP+ ni-MSCs or i-MSCs
after 21-day culture in the presence or absence of
PGCAP. We first demonstrated that MSCs remain GFP+
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after 21-day culture (data not shown). When these MSC-
loaded biomaterials were implanted in mice, GFP+/CD90+
cells were observed inside the pores of all types of bioma-
terials and inside PGCAP (Figure 6). These results suggest
that, after 4-week implantation, MSCs survived in the host
independently of the various tested conditions.
We then performed histological analysis on decalcified
biomaterials before and after 4-week implantation. We
showed that fibroblast-like cells were homogenously
detected in PGCAP and BMA (Figure 7) or BMF (data
not shown) pores just before implantation (see magni-
fied views of the boxed areas). After the implantation
period (Figure 7), vessels were observed in all biomater-
ials, suggesting that vascularization induction was not
dependent on the presence of PGCAP and osteogenic
induction. We observed that, after 4-week implantation,
the biomaterial exhibits large bone-like tissue zones
with some of the characteristics of woven bone (in
pores and PGCAP) when it was embedded in PGCAP
and loaded with ni-MSCs or i-MSCs (Figure 7). More
bone-like tissue zones were observed near the surface
than in the center of the biomaterial. When biomaterials
loaded with ni-MSCs were implanted in the absence of
PGCAP, we observed mainly areas of fibroid tissue.
Conversely, we observed few bone-like tissue zones
when the implanted biomaterials were loaded with i-
MSCs in the absence of PGCAP.
Quantification of bone-like tissue areas revealed that
PGCAP allowed higher bone formation in ni-MSC-
loaded biomaterials (12-fold for BMA, P <0.0001, and
106-fold for BMF, P <0.001; Figure 8a). Our result also
showed that osteogenic induction decreased bone-like
tissue formation area in biomaterial loaded by MSCs
and embedded in PGCAP (1.7-fold for BMA, P <0.0001,
and 2.6-fold for BMF, P <0.001; Figure 8a). Furthermore,
bone-like tissue formation areas in BMA loaded with ni-
MSCs and embedded in PGCAP were significantly
higher than in BMF (1.57-fold, P <0.01; Figure 8a).
Type I collagen immunohistochemical staining sec-
tions were performed on BMA and BMF before and after
Figure 4 Effect of PGCAP on mesenchymal stromal cell (MSC) and osteoprogenitor proliferation loaded on BMA and BMF. Not induced-
MSCs (ni-MSCs) or osteogenic induced-MSCs (i-MSCs) loaded on BMA and BMF biomaterials at high cell seeding density (20 × 10
3 cells per
biomaterial) were embedded or not in PGCAP and grown for 21 days. The number of cells was evaluated in each condition at days 10 and 21.
The data are expressed as mean ± standard error of the mean. A statistically significant difference between individual conditions (without
PGCAP) was revealed by analysis-of-variance test followed by Student Newman-Keuls. *P <0.05, **P <0.01. With PGCAP, similar tests revealed
statistically significant difference between group comparing ni-MSCs and i-MSCs loaded on BMA (
$*P <0.05) or group comparing ni-MSCs and i-
MSCs at day 21 (#**P <0.01). PGCAP, platelet glue obtained from cryoprecipitation of apheresis platelet products.
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implantation in mice. Before implantation, type I col-
lagen staining was limited to PGCAP area (Figure 8b).
After 4-week implantation, type I collagen staining was
observed in biomaterial pores and in PGCAP areas cor-
responding to the previously described bone-like tissue
zones. Furthermore, a higher type I collagen staining
was observed in biomaterials when they were embedded
in PGCAP as compared with the conditions in the
absence of PGCAP (data not shown). Together, our
results demonstrate that BMA was more efficient at pro-
moting bone-like tissue formation and suggest that the
addition of PGCAP leads to a higher stimulation of
bone-like tissue formation as compared with osteogenic
induction of MSCs.
Discussion
In recent years, the search for a substitute to cancellous
bone autograft in large bone defects has focused on
composite materials. Several parameters such as the nat-
ure of the conductive material, differentiation state of
implanted cells, and the local supplementation in
growth factors have been shown to be crucial in bone
Figure 5 PGCAP improves osteogenic differentiation of mesenchymal stromal cells (MSCs) loaded on biomaterials. Total RNAs were
extracted from ni-MSCs and i-MSCs loaded on BMA and BMF at high cell seeding density (200 × 10
3 cells per biomaterial) embedded or not in
PGCAP and grown for 21 days. Quantifications of osteopontin, type I collagen, Runx2, osteonectin, osteocalcin, and alkaline phosphatase mRNA
expression were analyzed by real-time quantitative-polymerase chain reaction. Transcript levels in arbitrary units are expressed as mean ±
standard error of the mean. A statistically significant difference between individual conditions or groups of condition was revealed by analysis-of-
variance test followed by Student Newman-Keuls test. Osteopontin: group of ni-MSCs and i-MSCs loaded on BMA embedded in PGCAP was
compared with other conditions ($*P <0.05). Type I collagen: individual comparisons, *P <0.05, **P <0.01, ***P <0.001. Runx2, Osteonectin: group
with ni-MSCs embedded in PGCAP (loaded in both biomaterials) was compared with other conditions with i-MSCs (#*P <0.05). Osteocalcin:
comparison of group osteogenic-induced or not (£*P <0.05). Alkaline phosphatase: group with i-MSCs without PGCAP (loaded in both
biomaterials) was compared with other conditions with ni-MSCs (§**P <0.01). i-MSC, not osteogenic induced-mesenchymal stromal cell; ni-MSC,
not induced-mesenchymal stromal cell; PGCAP, platelet glue obtained from cryoprecipitation of apheresis platelet products.
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repair. Owing to the number of parameters to be tested,
their relative importance and interactions still require
further basic research. We focused our study on a
blood-derived product as an easily available source of
clinical-grade growth factors: a platelet glue obtained
from cryoprecipitation of apheresis platelet products
(PGCAP). We showed that, in vitro, PGCAP enhanced
both proliferation and osteoblastic differentiation of
bone marrow-derived MSCs. We confirmed these results
by demonstrating the ability of PGCAP to improve ecto-
pic bone formation in mice after implantation of MSC-
loaded biphasic biomaterials. Interestingly, we showed
that this approach was more efficient than using MSC-
derived osteoprogenitor cells obtained after an in vitro
osteoblastic induction of MSCs.
Several teams have worked on platelet-derived product
optimization processes which led to various acronyms
such as (a) PRP [37], (b) concentrated PRP (cPRP) [38],
(c) ‘thorn PRP’ [39], and (d) ‘Choukroun platelet-rich
fibrin’ (PRF) [40]. Other studies reported that freezing/
thawing procedures allowed platelet lysate (PL) [17] or
cryoprecipitate (Cryo) [41] to be obtained. In our process
of PGCAP preparation, platelets were activated on a glass
support, leading to the initiation of coagulation without
requiring exogenous factors [42]. Then platelets were
successively frozen/thawed, allowing arrest of the coagu-
lation cascade, cryoprecipitation of plasmatic proteins
(such as fibrinogen). Platelet lysis induced by the process
allowed delivering platelet growth factors in the PGCAP.
As shown in our results, the PGCAP preparation process
allowed higher growth factor and cytokine concentra-
tions than other tested products (PPP, PL, TC, and FCS).
Moreover, Bieback and colleagues [43] showed that PL
was more powerful to enhance MSC proliferation, while
keeping their immune and differentiation potential, as
compared with human serum or thrombin-activated
PRP. PGCAP was obtained from apheresis products
which contain 1 × 109 platelets per milliliter and this is
Figure 6 Ex vivo confocal microscopy analysis of BMA and BMF biomaterials. Not induced- mesenchymal stromal cells (ni-MSCs) or
osteogenic induced-MSCs (i-MSCs) GFP+ loaded on BMA and BMF at high cell seeding density (200 × 10
3 cells per biomaterial) were embedded
or not in PGCAP and grown for 21 days. Next, biomaterials were subcutaneously grafted on nude mice. Unloaded biomaterials (no pre-loaded
cells and not embedded in PGCAP) were also grafted on mice. Twenty-eight days after grafting, biomaterials were cut in four pieces, fixed, and
stained with CD90 antibody. Biomaterials were analyzed by confocal microscopy (blue: biomaterial; green: MSC GFP+; red: CD90APC; and purple:
DAPI). Original magnification: ×20. Each picture is representative of three independent experiments. DAPI, 4’-6-diamidino-2-phenylindole; PGCAP,
platelet glue obtained from cryoprecipitation of apheresis platelet products.
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in agreement with the platelet concentration used by
Weibrich and colleagues [44] for bone repair. It is impor-
tant to note that our cryoprecipitation process leads to a
high growth factor concentration that does not alter
MSC and osteoprogenitor phenotype and their in vivo
capacity to form ectopic bone. Furthermore, in our pro-
cess, gel formation was obtained by using endogenous
fibrinogen and thrombin without the addition of several
Figure 7 Ectopic implantation of MSC-loaded BMA embedded in PGCAP promotes bone formation in nude mice. Not induced-MSCs (ni-
MSCs) or osteogenic induced-MSCs (i-MSCs) GFP+ loaded on BMA at high cell seeding density (200 × 10
3 cells per biomaterial) were embedded
or not in PGCAP and grown for 21 days. Next, biomaterials were grafted on nude mice. After 21 days of in vitro culture (before implantation)
and 28 days after grafting (after implantation), biomaterials were decalcified, embedded in paraffin, and stained with hematoxylin (nuclei),
phloxin (cytoplasm), and safranin (matrix). Original magnification: ×10. Boxed area is magnified and points out cells that have migrated in
biomaterials or area of bone formation. Arrows represent bone-like tissue characterized by osteocyte-like cells embedded in matrix stained by
safranin. Each picture is representative of three independent experiments. B, biomaterial; F, fibroid tissue; Pg, platelet glue obtained from
cryoprecipitation of apheresis platelet products; PGCAP, platelet glue obtained from cryoprecipitation of apheresis platelet products; V, vessels.
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chemical molecules [39] or xenogenic thrombin, that
could be of interest for a clinical application. Together,
these results confirmed the advantage of platelet lysis
combined with cryoprecipitation process to deliver
growth factors in the final product as compared with the
other platelet-derived products described above.
In addition to having a function in hemostasis, plate-
lets play an important role in inflammation and tissue
Figure 8 Bone formation areas are increased after ectopic implantation of MSC-loaded BMA embedded in PGCAP. (a) The average ratio
of bone formation area in BMA 28 days after grafting was determined in each condition. The data are expressed as mean ± standard error of
the mean. A statistically significant difference between individual conditions was revealed by analysis-of-variance test followed by Student
Newman-Keuls test. *P <0.05, **P <0.01, ***P <0.00, ****P <0.0001. (b) Type I collagen immuno-staining (brownish color) was performed on BMA
and BMF sections before implantation and 28 days after implantation. Original magnifications: ×4 and ×10. i-MSC, not osteogenic induced-
mesenchymal stromal cell; MSC, mesenchymal stromal cell; ni-MSC, not induced-mesenchymal stromal cell; PGCAP, platelet glue obtained from
cryoprecipitation of apheresis platelet products.
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wound repair through paracrine pathways or cell-cell
interactions [45]. Upon activation, platelets release a
wide range of factors that are involved in bone repair by
promoting survival and proliferation of various cells
(fibroblasts, MSCs, endothelial cells, osteoblasts, and
chondrocytes) [17,22]. Furthermore, some of these
growth factors (EGF, FGF, IGF-1, and SDF-1a) have
been shown to induce MSC osteoblastic differentiation
[46] whereas others (PDGF, TGF-b, and HGF) exhibit
controversial effects on osteogenesis depending or not
on MSC differentiation stages [47,48]. VEGF plays an
essential role in angiogenesis [49], and several studies
have investigated its role in the enhancement of fracture
healing and non-unions [50]. Moreover, these factors
released by platelets have chemotactic effects on various
cell types [51]. Thus, all of these observations support
the idea that platelet factors exhibit various effects pro-
moting bone regeneration.
The physical and chemical properties of biomaterials
are known to influence proliferation and differentiation
of MSCs and osteoformation in vivo. These parameters
also act on inflammatory reactions within the implanta-
tion bed. Malard and colleagues [52] suggested that a
strong but brief inflammatory reaction associated with
microparticles, which implies a massive release of cyto-
kines, was favorable to the bone-healing process. This
finding emphasized the importance of host response to
tissue-engineering devices [53]. In our study, moderate
inflammation was observed but no significant differences
were obtained with our various conditions. This indi-
cates that the difference of structure between Calcire-
sorb and Calciresorb bone like biomaterials did not
seem to influence this parameter.
The geometry and macrostructural properties of bio-
materials have been shown to play important roles: to
supply nutrients and oxygen, to allow infiltration of cells
and tissue, and to provide pores, channels, concavities,
or spaces in which processes leading to heterotopic
bone formation can occur without being disturbed by
high body fluid refreshments or mechanical forces. In
our study, confocal and histological analyses have shown
a good migration of cells in pores inside biomaterial for
both biomaterials (Figure 7). Higher bone formation
areas were obtained with Calciresorb biomaterial, sug-
gesting that a biomaterial combining macroporosity and
microporosity is able to promote a better osteoforma-
tion. This result is in agreement with literature showing
that microporosity and macroporosity are crucial for
osteoconductivity [54,55]. Moreover, the combination of
HA and TCP seems to be a useful association for gener-
ating a scaffold that allows a rapid vascularization and
integration during the early time point after implanta-
tion and a slow degradation [56,57]. In our study, diff-
erent results in terms of proliferation, osteogenic
differentiation, and osteoformation were obtained with
the two kinds of biomaterials tested. In fact, prolifera-
tion assays showed that Calciresorb bone like with 100%
TCP favored proliferation. However, in a biomaterial
with poor proliferative potential (BMA), PGCAP addi-
tion seemed to improve cell proliferation (Figure 4) and
allowed levels similar to those obtained with Calciresorb
bone like with 100% TCP to be reached. Even if BMF
exhibited high proliferative potential, no difference in
osteogenic marker expressions was obtained between
the two biomaterials tested.
The importance of enhancing the osteogenic potential
of MSCs/biomaterials has been investigated by pre-cul-
turing the seeded cells on scaffolds in the presence of
osteogenic media. Results from various studies suggest
that differentiation of the cells toward osteoblast lineage
and secretion of bone-like extracellular matrix may have
osteoinductive properties and promote in vivo bone for-
mation [58-60]. In our study, alkaline phosphatase
expression was upregulated in osteogenic pre-induction
conditions in vitro. However, the expression of other
osteogenic markers was not affected (Runx2) or was
slightly downregulated (osteopontin, osteonectin, osteo-
calcin, and collagen type 1) by this pre-induction step.
Results obtained in vitro are correlated to in vivo results
in which little bone formation was obtained with pre-
osteogenic induction. Compared with other studies, dif-
ferent results have been obtained and this is certainly
due to osteogenic medium composition or to the differ-
ence in the length of induction period necessary to
improve bone-inductive properties of constructs [32,61].
This observation raised the question of whether MSCs
need to be fully differentiated in osteoblasts and which
role they play in bone regeneration. Tortelli and collea-
gues [62] showed that the endochondral ossification
process is responsible for bone formation from host ori-
gin with MSC implants but that an intramembranous
ossification results from implants seeded by osteoblasts
(isolated from calvaria). This group also showed that
vascularization was increased in MSC implants and that
bone formation was more important in osteoblast
implants. Therefore, the quality and the type of ossifica-
tion appear to be dependent on the origin of cells
seeded on biomaterials. Other studies have confirmed
this result by showing that MSCs seeded on biomaterial
are able to recruit, first, host endothelial progenitors
and, next, osteoprogenitor cells [63]. MSC paracrine
potential might explain these results [31]. In fact, SDF-1
and its receptor CXCR4 are expressed by bone marrow
MSCs and promote both proliferation and survival of
these cells [64]. Furthermore, transduced MSCs secret-
ing high levels of SDF-1 displayed an enhanced ability
to form in vivo ectopic bone. Another study indicates
that SDF-1 secreted by MSCs induced recruitment of
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host progenitors and promoted survival and osteogenic
capacity of MSCs [65]. Adipose-derived stromal cells
have also been shown to induce osteogenic differentia-
tion of calvarial osteoblasts and to stimulate skeletal
repair via paracrine signaling [66]. Moreover, MSCs
loaded on subcutaneously implanted b-TCP biomaterials
are able to secrete a range of cytokines in the initial
post-implantation phase, which correlates with an
enhancement of bone formation in a later phase of
implantation [67]. This observation suggests that appro-
priate priming of MSCs is important to induce their
secretion of specific factors at the injury site.
As Kasten and colleagues [68] showed, the addition of
PRP increased alkaline phosphatase activity of undifferen-
tiated MSC composites but had little effect on ectopic
bone formation and only after 8 weeks. In agreement with
our datas, their results showed that a pre-induction with
chemical osteogenic inducers is not necessary for the pro-
moting effect of PRP on osteogenesis. Moreover, it had
been shown that osteogenic marker expressions were
induced in MSCs expanded in PL without the need of
osteogenic chemical inducers. In vivo, MSCs expanded in
PL enhanced bone formation compared with MSCs
expanded in FCS [30]. Our results also demonstrate that
PGCAP by itself is able to induce osteogenic markers
(type I collagen, osteonectin, osteopontin, and Runx2) and
that a combination with chemical osteogenic inducers is
not favorable since it decreases expression of osteogenic
markers (type I collagen, osteocalcin, osteonectin, and
Runx2). Reduced expression of alkaline phosphatase was
also obtained in PGCAP constructs placed in osteogenic
medium, as similarly shown by Bruder and colleagues
[47], who demonstrate that this alteration of alkaline phos-
phatase expression was dependent on the PDGF/ERK
pathway. In vivo, we have shown again that PGCAP highly
enhanced bone-like tissue formation and that the addition
of osteogenic medium decreased the effect of PGCAP. In
conditions with PGCAP, our result showed that cells were
well distributed both in glue and in pores, inside the bio-
material before implantation. This indicates that PGCAP
did not seem to hinder cell migration. In conditions with
PGCAP, we consider that diffusion of nutrients in vivo
was equivalent in conditions with a pre-osteogenic induc-
tion or not. Even if cells embedded in PGCAP interacted
with an environment different than those present in pores
inside biomaterial, the addition of PGCAP improved
bone-like tissue formations in both biomaterials (Figure
8). Future experiments should be done to test the combi-
nation of PGCAP with biomaterial and MSCs in a model
of large bone defect. With a subcutaneous ectopic model
of bone formation, we did not explore the impact of
mechanical constraints that occur in bone defect and the
impact on biomaterial degradation and further bone remo-
deling. However, our combination should have some
interest in large bone defect. Indeed, gel formation
obtained from PGCAP represents an advantage in surgical
procedure to treat bone defect. PGCAP also contains var-
ious chemokines, such as SDF-1, that could play a role in
host progenitor cell recruitment, as demonstrated in our
study by the presence of a high number of host cells on
the implanted biomaterials (data not shown). Finally,
PGCAP is enriched in survival growth factors, such as
HGF, IGF-1, and SDF-1, that could play an important role
for improving the local survival of implanted MSCs.
Furthermore, we demonstrate that PGCAP acts on prolif-
eration and differentiation of MSCs that could be of inter-
est in large bone defect.
Conclusions
Our data on osteoblastic gene expression and on in vivo
ectopic bone formation confirm that MSCs embedded
in PGCAP did not require osteogenic pre-induction for
exhibiting a significant osteoblastic differentiation and in
vivo bone formation. Moreover, Calciresorb biomaterial
(65% HA/35% TCP) was more powerful in promoting
osteoformation. Taken together, our results indicate that
the combination of Calciresorb biomaterial and PGCAP
to MSCs is more efficient than the combination of
Calciresorb biomaterial to osteogenic-inducted MSCs
and offers an attractive alternative to autologous bone
graft for bone tissue engineering.
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